Description
Non-Fucosylated Anti-Human CD70 (2H5) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Autoimmune diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD70 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD70
Full Name
CD70 Molecule
Background
CD70 (CD70 Molecule) is a Protein Coding gene.
Diseases associated with CD70 include Acute Myocarditis and Lymphoproliferative Syndrome 2.
Among its related pathways are PEDF Induced Signaling and Cytokine Signaling in Immune system.
Gene Ontology (GO) annotations related to this gene include receptor binding and protease binding.
Alternative Names
Vorsetuzumab; 1165740-62-4; SGN-70; h1F6; CD70; CD70 molecule; CD27LG, TNFSF7, tumor necrosis factor (ligand) superfamily, member 7; CD70 antigen; CD27L; CD27-L; CD27 ligand; Ki-24 antigen; surface antigen CD70; tumor necrosis factor ligand superfamily member 7;
Gene ID
970
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
2H5
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Autoimmune diseases
